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The aim of the present study is to evaluate, in a ligature-induced peri-implantitis model, the
efficacy of three antimicrobial glassy coatings in the prevention of biofilm formation, intrasul-
cular bacterial growth and the resulting peri-implant bone loss.
Methods
Mandibular premolars were bilaterally extracted from five beagle dogs. Four dental implants
were inserted on each hemiarch. Eight weeks after, one control zirconia abutment and
three with different bactericidal coatings (G1n-Ag, ZnO35, G3) were connected. After a pla-
que control period, bacterial accumulation was allowed and biofilm formation on abutments
was observed by Scanning Electron Microscopy (SEM). Peri-implantitis was induced by cot-
ton ligatures. Microbial samples and peri-implant crestal bone levels of all implant sites
were obtained before, during and after the breakdown period.
Results
During experimental induce peri-implantitis: colony forming units counts from intrasulcular
microbial samples at implants with G1n-Ag coated abutment remained close to the basal
inoculum; G3 and ZnO35 coatings showed similar low counts; and anaerobic bacterias
counts at control abutments exhibited a logarithmic increase by more than 2. Bone loss
during passive breakdown period was no statistically significant. Additional bone loss
occurred during ligature-induce breakdown: 0.71 (SD 0.48) at G3 coating, 0.57 (SD 0.36)
at ZnO35 coating, 0.74 (SD 0.47) at G1n-Ag coating, and 1.29 (SD 0.45) at control
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abutments; and statistically significant differences (p<0.001) were found. The lowest bone
loss at the end of the experiment was exhibited by implants dressing G3 coated abutments
(mean 2.1; SD 0.42).
Significance
Antimicrobial glassy coatings could be a useful tool to ward off, diminish or delay peri-
implantitis progression.
Introduction
Bone preservation around implants constitutes a primary criterion for implant success [1, 2].
But nowadays, one of the most important problems related to dental implant therapy is to pre-
serve the osseointegration achieved. Peri-implantitis is an inflammatory reaction in the tissues
surrounding a dental implant and is characterized by loss of supporting bone [3]. While early
implant success rates are undisputed high (97–98%) [4], peri-implant disease has emerged as
the main threat for implant health and depending on its severity, implant failure can occur
(approximately 11% after 10 years of function) [5, 6]. In contrast to periodontal tissues, peri-
implant tissues appeared to be poorly encapsulated to resolve progressive. Plaque-associated
lesions are extended into the marginal bone tissue and may, if they are allowed to progress,
lead to the loss of the implant [7, 8].
“Peri-implant diseases are infectious in nature” [3]. For the first time, the association
between bacterial plaque biofilm formation and the pathogenesis of peri-implant diseases was
demonstrated in animal studies. In this experimental model, mucositis and peri-implantitis
lesions were induced by terminating the plaque control regimen and the placement and
exchange of ligatures around the implant neck in a submucosal position [9].
The growing resistance of microorganisms to antibiotic therapy acquires increasingly
greater concern as infectious diseases may progress uncontrolled. A particular problem is
found with infections caused by biofilms, like peri-implant disease, where a variety of factors
can contribute to a greater resistance to antibiotics compared with bacterias in planktonic sta-
tus [10]. To cope with this problem, attention has been focused on inorganic antimicrobial
solutions and great efforts have been paid in the field of nanotechnology [11]. At present, the
most important research activity has been performed on materials supporting or carrier silver
or copper nanoparticles [12–14]. But since the limits of systemic toxicity effects on human
health of metal nanoparticles are still unknown [15], a new generation of “green antimicrobi-
als” have been tailored to exhibit prescribed antimicrobial attributes, with microstructure and
dissolution rates programmed to match each specific application and with no adverse effects
on the host ecology [16, 17]. They are based on two families of glasses belonging respectively to
B2O3-SiO2-Na2O-ZnO and SiO2-Na2O-Al2O3-CaO-B2O3 systems. One is a ZnO enriched
glass and the other one a CaO enriched glass. The antimicrobial capability of the glass enriched
with CaO relies on close contact with the target cells [18, 19]. On the contrary, in the case of
the ZnO enriched glass it is attributed to the release of Zn2+ [20].
The aim of this study is to evaluate the efficacy of these new antimicrobial glassy coatings by
inhibiting bacterial growth in subgingival sulcus and preventing peri-implant marginal crestal
bone loss. For a comparative purpose, a soda-lime glass containing silver nanoparticles is also
evaluated. The efficacy of this kind of glass to prevent peri-implant diseases was pointed out in
previous works [21, 22]
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Data from human studies are often considered to provide the highest level of scientific evi-
dence but for ethical reasons, experimental studies of peri-implant infections cannot be con-
ducted in humans. Hence, the information gathered in this field must rely on animal studies.
Nevertheless, ethical considerations must be made also when planning experiments using ani-
mal models. In this sense Kilkenny et al. [23] presented the ARRIVE guidelines intended as a
guide when preparing on animal research.
Therefore, experimental studies must be carefully designed to allow for valid outcome
assessments. Since animal studies have indicated that the histopathological characteristics of
these experimentally induced peri-implantitis lesions have many features in common with nat-
urally occurring lesions [24], this model seems to have a relevance to human biology. Beagle
dogs exhibit a natural susceptibility to periodontal disease [25] and reveal a jaw bone anatomy
usually facilitating the insertion of common dental implants. In addition, their easy manage-
ability facilitates postoperative oral hygiene procedures. This explains why Beagle dog appear
to be the most suitable animal to conduct the ligature-induced peri-implantitis defect model.
Material and Methods
2.1. Antimicrobial Glasses
In previous studies [18, 20, 26] the antimicrobial capability of different antimicrobial glasses
was proven against various microorganisms. Three of those glasses were selected as precursors
of the bactericidal coatings: i) a soda-lime window-like glass with silver nanoparticles labeled
as G1-nAg [26], ii) a soda-lime glass from the SiO2-Na2O-Al2O3-CaO-B2O3 system labeled as
G3 [18], and iii)a glass belonging to the B2O3-SiO2-Na2O-ZnO system labeled as ZnO35 [20].
Glasses without silver nanoparticles were prepared by melting appropriate mixtures of
reagent grade SiO2, α-Al2O3, H3BO3, Na2CO3, CaCO3, ZnO (Sigma-Aldrich). The starting
materials were weighed, mixed and melted in a Pt crucible for 1 h at 850°C to favor decarbon-
ation of samples, and subsequently for 1 h at 1400°C (G3) and at 1250°C (ZnO35). Chemical
composition of these glasses is shown in S1 Table. On the other hand, homogeneous dispersed
silver nanoparticles (10–90 nm) embedded into glassy matrix with a content of silver of 20 wt.
% was prepared according to the method developed by Esteban-Tejeda et al. [26].
2.2. Preparation of the coated abutments
Coatings were prepared following different procedures depending on the type of glass used. In
the case of the glass containing silver nanoparticles, the coatings were obtained following a sim-
ilar procedure that the one described in a previous work [21]. Briefly, the green coating was
obtained by dipping the zirconia abutments into an ethylene glycol glass-nAg powder suspen-
sion with 70 wt.% solid content. The abutments were vertically dipped into the suspension for
3 seconds, and then withdrawn at the same speed. The resulting coatings were dried at room
temperature for 24 h. The green coated abutments were subsequently heated in air atmosphere
at 880°C for 2 h.
Coatings using antimicrobial glasses without silver nanoparticles were done by screen-print-
ing technology. A polymer ink, based on a mixture of epoxy and glass powder was prepared for
the glass layer screen-printing. This layer was deposited on the corresponding substrate sur-
face. The green-coatings of ZnO35 prepared as indicated were fired in air atmosphere at 750°C
for 30 min (temperature ramp 10°C/min). In the case of the green-coatings of G3 were fired in
air atmosphere at 1100°C. The rate of cooling was adjusted to be rapid enough (> 300°C/min)
to avoid crystallization as well any cracking or chipping phenomena.
Antimicrobial Coatings in Implants
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2.3. Animals
The study protocol was approved by the Ethics Committee for Animal Research Welfare, Mini-
mally Invasive Surgery Centre, Cáceres, Spain. Five male Beagle dogs were used in this experi-
ment to accomplish with the goal of reduction, the second of the 3R’s (Replacement, Reduction
and Refinement) widely accepted ethical framework for conducting scientific experiments. In
addition, it is usual to employ this number of animals for this kind of experiments and satisfy
statistical power requirements. Dogs at the initiation of the experiment were 12 months old
and 13.5 kg mean weight.
The out line of the experiment is presented in Fig 1. Refined dog husbandry and care was
provided all along the study. During all procedures, veterinary assistance was used continu-
ously and all efforts were made to minimize suffering. General anesthesia was induced with
intravenous injected propofol 10 mg/kg (Propofol Hospira, Hospira Productos Farmacéuticos
y Hospitalarios, Madrid, Spain). N°7 endotracheal tube with a balloon cuff was placed and con-
nected to a circular anesthesia circuit (Leon Plus, Heinen & Löwenstein, Bad Ems, Germany).
The anesthesia was sustained with sevofluorano (Sevorane, Abbott Laboratories, Madrid,
Spain). Multimodal analgesia was employed in the perioperatory (ketorolac 1 mg/kg (Toradol
30 mg, Roche);—tramadol 1.7 mg/kg (Adolonta inyec., Grünenthal); and—buprenorfine 0.01
mg/kg (Buprex, Reckitt Benckiser Pharmaceuticals Limited, Berkshire, UK).
2.4. Surgery
All mandibular premolars and molars were extracted. After three months of healing, mucoper-
iosteal flaps were elevated and 4 fixtures (MIS Implants Technologies Ltd., Israel; Implant
Seven: length 10, diameter 3.75) were installed in the edentulous region on both sides of the
mandible. A total of 40 implants were placed in the five male Beagle dogs. During this period
animals were feed with a soft diet. Eight weeks later, second stage surgery was performed and
machined zirconia abutments were attached. Mesial implants of each quadrant -implant num-
ber 1- (see Fig 2) supported machined zirconia abutments without any coating and were con-
sidered as control implants. The other 3 implants in each quadrant dressed antimicrobial
glassy coated zirconia abutments, and were considered case implants. For implants in position
number 2, ZnO-glassy coating was provided; for implants in position number 3, G3 glassy
coating was dressed; and for implants in the most distal position n-Ag coating was allocated.
A plaque control program was initiated. This included cleaning of teeth and abutments,
once a day, 5 days a week, with toothbrush and dentifrice. The plaque control regimen was
Fig 1. Outline of the study. This figure describes the actions conducted during the principal phases of this
study. The preparatory period consisted in dental extractions, a healing period, dental implants installation,
abutments connection and a plaque control regimen. During passive breakdown period all plaque control
activities were stopped and afterwards, peri-implantitis was additionally induced by intrasulcular placement of
cotton ligatures during an active breakdown period. PC- Plaque Control. PF- Plaque Formation.
doi:10.1371/journal.pone.0140374.g001
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terminated four weeks later. At the end of the plaque control period, animals were exposed to
clinical and radiological examinations, and bacterial samples were collected. Visual signs of
gingival inflammation, such as redness and swelling, were evaluated and digital radiographs
were obtained from all implant sections at the beginning and the end of experiment, and twice
in the transition from passive to active peri-implant breakdown period (weeks 24, 36, 38 and
46) (See Fig 1). We used a holder that allowed easy and predictable alignment of the X-ray
tube, and reproducible radiographic images from which highly repeatable measurements could
be made. The radiographs were analyzed using Nemotec Dental Studio1 Software (Nemotec
SL, Madrid, Spain) and the distance between the abutment-fixture junction (A/F) and the mar-
ginal position of bone-to-implant contact (BIC) was determined. The measurements were
made at both the mesial and the distal aspect of each implant and were redone after 1 week to
confirm intraobserver reliability.
Bacterial samples were collected at 4 aspects of each implant (buccal, lingual, mesial and dis-
tal) by introducing sterilized paper points (n° 30, Mayfeller) into the peri-implant sulcus.
Colony forming units per milliliter (CFU/mL) were used as a measure of the number of
microorganisms present in a sample. Samples were shaked and then spread uniformly on a sur-
face of a blood-agar plate for aerobes count, on a surface of Brucella for total bacterial count,
and then incubated at 35°C for 48 hours.
2.5. Passive breakdown period (spontaneous bacterial accumulation)
The plaque control regimen was finished and thus the plaque was allowed to accumulate dur-
ing the course of the following twelve weeks. Once a week a clinical examination was per-
formed to asses the plaque, soft tissue inflammation. At the end of this period, radiographs
were obtained to assess changes in bone loss related to spontaneous plaque accumulation. Bac-
terial samples were also collected at this point to report CFU counts at different coatings.
Fig 2. Diagram of implants locations. N°1: Control abutment. N°2: G3 coated abutment. N°3: ZnO35
coated abutmet. N°4: G1n-Ag coated abutment.
doi:10.1371/journal.pone.0140374.g002
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Afterwards, all zirconia abutments were replaced to assess coating wearing down and to ensure
coating integrity during next phase of the experiment. Retrieved abutments were characterized
at this point as following: The surface and cross section morphology were analyzed by Field
Emission Scanning Electron Microscopy (FESEM) (FEI: Quanta FEG650) with an associated
energy dispersive spectroscopy analysis (EDS) (EDAX-AMETEK).
2.6. Active breakdown period (ligature-induced peri-implantitis)
Cotton ligatures were placed in a submarginal position around the neck of the new abutments
according to the technique described by Ericsson et al. [27] and Lindhe et al. [9]. Once a week a
clinical examination was performed to asses the plaque, soft tissue inflammation and the pres-
ence of ligature. The ligatures were replaced every three weeks with new ligatures placed in the
pocket of the receded gingival margin. At the end of the experimental peri-implantitis a new
radiographic and clinical examination was performed. Animals were euthanized with a lethal
dose of Sodium-Penthotal1 (B. Braun Medical SA. Rubí. Barcelona. Spain) and mandibular
blocks containing fixtures were retrieved and stored in a 5% formaldehyde solution (pH 7).
The implants were individual retrieved from the jaw bone using an oscillating autopsy saw.The
retrieved specimens were immediately immersed in a solution of 4% formaldehyde and 1% cal-
cium. The specimens were embedded in methyl-methacrylate and stained with combined basic
fuchsin and toluidine blue. Transverse sections perpendicular to the beagle bone jaw with a
thickness of approximately 80 μm were obtained for descriptive histology.
The biopsy specimens were processed immediately to obtain undecalcified thin ground sec-
tions, following Donath's method. The preparations were dyed with Harris Hematoxiline
(Papanicolau, Merck, Germany) and Wheatley's modification of thrichromic stain (Chromo-
trope 2R, Newcommersupply, USA) and preserved with Canada balsam solution (Fluka Bio-
chemika, USA). Preparations were examined by using a transmitted light microscope
(Optiphot, Nikon, Japan) equipped with a digital Camera (DP-12, Olympus, Japan).
2.7. Statistical analysis
Mean values for all variables were calculated. Comparisons were made using absolute values
(initial and final bone loss) and changes in a relative scale ((initial-final) / initial). Differences
were analyzed in pairs (control group versus tested coated groups) using non-parametric
(Mann-Whitney; Wilcoxon) methods. The null hypothesis was rejected at p<0.05.
Results
Characterization of the coatings before being implanted in dogs
Scanning electron micrographs of the top surface and of the cross section of the different coat-
ings are shown in Fig 3. No crystallization was observed in the case of the coating made of glass
G3 (Fig 3A), whereas it is clearly visible when glass ZnO35 is used (Fig 3C). These crystalliza-
tions were identified by XRD (data not shown) as sodium zinc silicate crystals Na2ZnO2(Si2O7)
and willemite crystals (Zn2SiO4). Thermal expansion coefficients of the glasses [αZnO35 = 10.7
10−6 K-1, αG3 = 14.210−6 K-1, αGlass-nAg = 1110−6 K-1], and of the 3Y-TZP substrate (α3Y-TZP =
10.6 10-6K-1) are quite similar [17], so not visible cracking was observed in any of the coatings.
In the case of the coating made of glass containing silver nanoparticles (Fig 3E), silver particle
size ranges between 20–90 nm but also some agglomerates (0.5–1.8 μm) are present. The aver-
age starting coating thickness was found to be 23.1 μm for G1-nAg coating, 3.6 μm for G3 coat-
ing, and 7.9 μm for ZnO35 respectively.
Antimicrobial Coatings in Implants
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Characterization of the coatings after three months being implanted in
dogs
Characterization of the coatings after three months was done by scanning electron microscopy
(SEM). It is worth to point out that all abutments still had part of the original coatings,
although at lingual aspect G1n-Ag coating wore down significantly because of the abrasiveness
of the dog’s tongue. Bacterial cells colonized densely onto the surface of the uncoated zirconia
abutment (Fig 4A and 4B). Conversely, the extend of bacterial adhesion on the glass coated
abutments decreased significantly, and only few microorganisms appear located on the coating.
By the way of example, biofilm formation occurred only in the part of the abutment free of
coating (Fig 4C) and significantly few microorganisms are shown in the abutment coated with
glass G3 (Fig 4D). Biofilm formation onto the surface of ZnO35 (Fig 4E and 4F) and G1n-Ag
(Fig 4G and 4H) coatings was much lower than in the case of control uncoated zirconia abut-
ments. These micrographs are very consistent with the microbiological tests.
Fig 3. Scanning electron micrographs showing the surface of the glassy coatings: A) G3, C) ZnO35,
E) G1n-Ag, and the cross section: B) G3, D) ZnO35 and F) G1n-Ag.
doi:10.1371/journal.pone.0140374.g003
Antimicrobial Coatings in Implants
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Microbiological Tests
Weighted means of the CFU counts per mL are shown in Fig 5. G1n-Ag abutments maintained
a baseline of anaerobic bacteria counts all along the experiment. We also emphasize that G3
and ZnO35 coated abutments had a similar effect. Conversely, control abutments without any
bactericidal coating experienced a logarithmic increase of anaerobic CFU up to 2.36, which is
not compatible with infection control. All coatings (G3, ZnO35 and G1nAg) developed along
similar lines for aerobic bacteria, with CFU means closed to the primary inoculum. On the con-
trary, control abutment exhibited an increase over time.
Clinical examinations
At the second stage surgery, one implant planned to be used as a G1n-Ag case-implant was lost
(dog 794 microchip code). Therefore a total of 29 implants were successfully osseointegrated.
Clinical examinations performed at the beginning of the experimental induced peri-implantitis
period revealed important gingival inflammation around the G1n-Ag and slight inflammation
around ZnO35 biocidal coated abutments and minimal changes around control implant’s gin-
giva. These observations were progressively changing over, so that at the end of the experiment
control implants presented important gingival inflammation while all biocide coated implants
showed minimal gingival changes (Fig 6). A large amount of plaque was harbored at the con-
trol implants while at the biocidal coated implants plaque retention was located at ligature,
despite the rough surface of the coating. There were no adverse events during experimental
procedures.
Radiographic assessments
The distance from the implant shoulder to the alveolar bone crest changed to a greater or lesser
extend depending on the abutment coating (Fig 7). Fig 8 displays bone loss progression at
Fig 4. Scanning electronmicrographs at different magnifications of: A and B) uncoated zirconia abutment, C and D) G3 glassy coated zirconia
abutment, E and F) ZnO35 coated zirconia abutment, G and H) G1n-Ag coated zirconia abutment.
doi:10.1371/journal.pone.0140374.g004
Antimicrobial Coatings in Implants
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different coatings during experimental induce peri-implantitis (passive breakdown -weeks 24
to 36- plus active breakdown -weeks 36 to 46-); and S2 and S3 Tables show statistical results.
From Fig 8 we can see that at the end of plaque control period (week 24) bone loss mean val-
ues were 0.5mm (SD 0.44) at position 1; 0.45mm (SD 0.39) at position 2; 0.8mm (SD 0.77) at
position 3; and 1.2mm (SD 0.47) at position 4. Significant statistical differences (p<0.001) in
Fig 5. Logarithmic progression in CFU/mL of intrasulcular samples during experimental induced peri-
implant disease: A) Aerobic bacterial counts, B) Anaerobic bacterial counts.
doi:10.1371/journal.pone.0140374.g005
Fig 6. A) Intrasulcular sampling with sterile paper points at week 24. B) Clinical view of gin- gival
inflammation at week 46. 1. Uncoated zirconia abutment, 2. G3 glassy coated abutment, 3. ZnO35 coated
abutment, 4. G1n-Ag coated abutment.
doi:10.1371/journal.pone.0140374.g006
Antimicrobial Coatings in Implants
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bone loss were found between position 4 and positions 1 and 2, but this was no the case for
position 1 vs 2 (p 0.86), 1 vs 3 (p 0.31), 2 vs 3 (p 0.16) and 3 vs 4 (p 0.026).
Once this initial and spontaneous bone remodeling is originated and plaque accumulation
is allowed, no statistical significant (p 0.29) differences in mean bone loss around implants are
showed during passive breakdown period (S2 Table). On the contrary, during the active break-
down period (ligature induced peri-implantitis) additional bone loss occurred (Fig 8). This
additional bone loss varied considerably between control and case implants (S2 Table). In an
absolute scale, the difference variable (initial mean value—final mean value) shows a significant
additional bone loss at control implants (p<0.001). When we used a relative scale ((initial-
final)/ initial) to quantify additional bone loss during active breakdown period a percentage
change of 221% was observed at control implants. Percentages of additional bone loss observed
in implants dressed with a biocidal coated abutment were about 124% lower (p<0.001) than
the control ones.
Total bone loss expressed in absolute values was 2.21 mmmean (SD 0.46) for control abut-
ment, 1.64 (SD 0.43) for G3 coating, 1.42 (SD 0.40) for ZnO35 coating, and 1.45 (SD 0.56) for
G1n-Ag coating. The lowest final mean bone loss was exhibited by implants that dressed G3
coated abutments (mean 2.1; SD 0.42). From S3 Table we can infer that significant statistical
Fig 7. Digital radiographs of implants at the beginning of the plaque formation period in week 24 (A)
and at the end of the study in week 46 (B). Differences in crestal bone level are evident. 1. Uncoated
zirconia abutment, 2. G3 glassy coated abutment, 3. ZnO35 coated abutment, 4. G1n-Ag coated abutment.
doi:10.1371/journal.pone.0140374.g007
Fig 8. Bone loss progression at different coatings during experimental induced peri-implantitis
period.
doi:10.1371/journal.pone.0140374.g008
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PLOS ONE | DOI:10.1371/journal.pone.0140374 October 21, 2015 10 / 16
differences (p<0.001) in absolute (difference) and relative (change) mean bone loss values
were found between coated abutments and control ones.
The results from the reproducibility assessments of the radiographic measurements revealed
small differences between the two assessments. The intra-observer mean difference was 0.09,
and variance and standard deviation were 0.06 and 0.23 respectively.
All of the above is in accordance with results presented in Fig 9, where cross section A (cor-
responding with an implant wearing uncoated zirconia abutment) shows a bone resorption
process that forms a crater defect and reduce bone-to-implant contact level to the macro-
threads zone of the implant; and cross section B (corresponding with an implant wearing G3
glassy coated zirconia abutment) sustain an evident lesser bone loss limited to the micro-
threads zone and do not incur in the typical crater shape bone defect associated with active
peri-implantitis. A completed histological and histomorphometric analysis of the different
gross sections obtained from the implants is in progress.
Discussion
In the present study microbial and marginal bone levels at implants subjected to experimental
peri-implant disease were analyzed. The different types of abutments included in the experi-
ment, which differed with regards to coating, exhibited dissimilar competence for effective
microbial load control and bone resorption around implants.
Fig 9. Transversal sections of implants at the end of the study in week 48. After a passive plaque
formation period and an active ligature induce peri-implantitis period: A) An implant wearing uncoated
zirconia abutment shows a bone resorption process that forms a crater defect and reduces bone-to-implant
contact level to the macro-threads zone of the implant. B) An implant wearing G3 glassy coated zirconia
abutment undergoes an evident lesser bone loss limited to the micro-threads zone and does not display the
typical crater shape bone defect associated with active peri-implantitis.
doi:10.1371/journal.pone.0140374.g009
Antimicrobial Coatings in Implants
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Scanning electron microscopy (SEM) of the coatings three months after being implanted in
dogs proved that structural integrity is preserved. It is further observed that glassy coatings
decrease bacterial attachment and proliferation on its surface (Fig 4). Large clusters of bacteria
can be clearly observed on control abutment, while only few bacillus shaped bacteria are barely
spotted. In the same line other studies showed inorganic nanoparticles as a coating material to
inhibit bacterial adhesion and promote osteoblast growth [28].
CFU counts from intrasulcular samples resulted in consistent findings of SEM abutment
analysis. No statistical significant differences were detected in aerobic bacterial counts between
control or coated abutments, but a slight increase in CFU from basal inoculum was evidence in
control abutments as experiment evolved. It should be noted that, whilst control abutments
experimented a logarithm of increase> 2 for anaerobic cfu/ml, the antimicrobial study of
these glassy coatings pinpointed that this new family of bactericidal glasses is very effective
maintaining anaerobic bacterias levels close to the basal inoculum logarithmic concentration
(Fig 5B).
“In vitro” experiments previously reported [17, 29, 30] had documented that this new family
of biomaterials is very effective diminishing (logarithm of reduction>3) the growth of bacteria
(such as S. aureus, E. coli, S. epidermidis,M. lutea and P. aeruginosa) as well as yeast (C. Krusei).
Microbiological results regarded from this dog experiment allow us to assert that the same “in
vivo”microbial counts control effectiveness is exhibited. This is also quite consistent with clini-
cal findings (Fig 4), where at week 24 minimal gingival inflammation is observed at positions 3
(ZnO35) and 4 (G1n-Ag) and no gingival changes at all can be pinpointed at position 1 (con-
trol) and 2 (G3). Nevertheless, at the end of induce peri-implant disease the reverse happens.
At week 46 plenty of suppuration arise from sulcus in control abutment position 1 and
adversely affecting the medial aspect of position 2 (G3); it is noteworthy that positions 3
(ZnO35) and 4 (G1n-Ag) hardly exhibit any gingival inflammation in spite of bacterial accu-
mulation caused by sub-gingival cotton ligatures.
Previous experiments [9, 31, 32] have demonstrated that mucositis and peri-implantitis
may be induced by terminating the plaque control regimen (passive breakdown) and the place-
ment and exchange of ligatures around the implant neck in a sub-mucosal position (active
breakdown). Fig 7 shows radiological crestal bone level at the beginning and end of peri-
implant induce disease. All implants exhibited bone loss to a greater or lesser extend depending
on the abutment coating dressed.
The mean amount of bone loss that occurred during the preparatory period (implant inser-
tion-plaque control cessation) can be seen from Fig 8. Mesial and distal aspect of each implant
were considered observation units (n = 20) to assess bone loss. All abutments with the excep-
tion of G1n-Ag, experimented similar bone loss during plaque control period that could possi-
bly be explained by biological width development. Similar results occurred in an earlier study
looking at bone loss around implants wearing G1n-Ag coated abutments [21]. This spontane-
ous bone loss around implants dressed with G1n-Ag coated abutments during plaque control
phase, and previous to the induce peri-implant disease period, could be related to a time-lim-
ited minimal gingival inflammatory reaction triggered by the coating material itself (Fig 6).
Similar inflammatory reaction was shown to a lesser extend by ZnO35 coated abutments, but
no inflammatory changes were triggered by control nor G3 coated abutments.
No statistical differences (p<0.29) in bone loss have been shown during passive breakdown
period. This is in concordance with the slight increase of bacterial counts assessments from
intrasulcular samples at this period. It is worth noting that during ligature induce peri-implan-
titis (active breakdown period) differences in bone loss were statistically significant (p<0.001)
between control abutment and all coated abutments, both for absolutes values (difference vari-
able) and for relative values (change variable). This is directly linked to anaerobic bacterial
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logarithmic increase caused by ligatures. The more bacterial counts increase the more bone
loss exhibited around implants. G1n-Ag showed the best bacterial control counts (Fig 1B) and
one of the lowest bone loss in absolute values (total difference) (S2 Table). Nevertheless, due to
the time-limited spontaneous bone resorption that these coated abutments exhibited during
plaque control period, from Fig 8 we can see that total final bone loss at week 46 was similar to
control abutments. Antimicrobial properties of ZnO35 and G3 coatings were similar and
closed to G1n-Ag coating, and therefore bone loss during ligature induce peri-implantitis
around implants that dressed these coatings (positions 2 and 3) resulted statistically significant
(p<0.001) low when compared with control abutments. Indeed, from S2 Table can be seen
than ZnO35 coating exhibited the lowest total bone loss expressed in an absolute value (initial
bone level assessment minus final bone level value). However, as in the case of G1n-Ag coating,
ZnO35 coatings went through a time-limited bone resorption process during initial plaque
control period, although to less extension. This provoked a total final bone loss of 2.25 mm at
week 46 even though it has exhibited exceptional antimicrobial properties during active break-
down period. It is noteworthy that G3 coated abutments exhibited the lowest mean bone loss
compared with controls or any other antimicrobial coating all along the experiment and at the
final point at week 46.
It is realized that there is a concern with metal-based nanomaterials—engineered metal and
metal oxide nanoparticles—to human health [33], but in spite of all efforts made to clarify the
limits of such toxic health effects, there is still insufficient evidence to support the claim [15, 34].
In the present study animals did not exhibit any coating related adverse effect further than
initial time-limited gingival inflammation assessed around ZnO35 and G1n-Ag coatings. It
should be pointed out that G3 coating did not exhibit this initial gingival inflammation. Any
health hazard risk was showed neither in clinical nor analytical evaluations of animals per-
formed all along the experiment.
Experimental models in animals were established to evaluate tissue reactions in relation to
the use of dental implants. It is realized that this model may not mimic the onset and/or pro-
gression of natural disease in humans, but comparisons between lesions produced with such
models exhibit features similar to those found in human biopsy material [24]. It is acknowl-
edged that ethical considerations prevent complete analysis of pathogenesis on peri-implant
diseases in humans, which explains the use of preclinical in vivomodels.
Conclusions
As it is evident from the results presented in this study, all the studied glassy coatings exhibit
antimicrobial properties that avoid bacterial attachment to abutment and keep bacterial prolif-
eration under control in the peri-implant sulcus. These glass coatings are particularly effective
preventing anaerobic bacterial growth, which are the ones directly associated with the peri-
implant disease.
Further, our analysis indicates that radiologic resorption around implants due to experi-
mentally induced peri-implantitis is significantly large in implants dressed with control abut-
ments compared with implants dressed with glassy antimicrobial coatings. This bone
resorption prevention is especially apparent in G3 coated abutments and also in less extension
in the case of ZnO35 coated abutments.
There is a need for an analysis of the clinical course of bone resorption around coated
implants placed in patients with high risk of peri-implantitis. Therefore, clinical trial designs
dealing with antimicrobial glassy coatings are an urgent must. In clinical practice, it shall be
develop and implement suitably effective coating strategies on definitive prosthetic transgingi-
val abutments or on zirconia crowns.
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